Overview

MK0429 Study in Prostate Cancer Patients With Metastatic Bone Disease (0429-011)

Status:
Completed
Trial end date:
2007-10-01
Target enrollment:
Participant gender:
Summary
This two part study will evaluate the safety and tolerability of MK0429 in addition to assessing it's pharmacokinetic profile and pharmacodynamic response.
Phase:
Phase 1
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.
Treatments:
Hormones